Biocon, Bristol-Myers sign drug deal
- Manmohan Singh is India's "weakest PM": L K Advani
- 'Shahzada' and 'Matashree' are only concerned about being in power, says Modi; Sonia harps on secularism
- Modi has deep character flaws... wouldâve fought in Varanasi if I knew Hindi: PC
- Supreme Court commutes death penalty of Devinderpal Singh Bhullar to life term
- March 31 Campaign roundup: BJP to release party manifesto on April 3; Kejriwal's meeting with the LG a drama to mislead people, says Cong
Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide licence to its oral insulin drug programme.
Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.
Biocon, which has been looking to partner the drug for nearly two years, said it would receive a licence fee as well as milestone payments and royalties based on commercial sales of the drug outside India.
It will retain the rights to IN-105 in India. Financial terms of the deal were not available.
Currently, there are no insulin tablets available and patients with diabetes who need insulin – a naturally occurring protein that controls blood sugar – must inject it.
Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.
Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.
Company INFO More on Biocon
Stocks More on Biocon
Biocon inks pact with Bristol-Myers for insulin drug candidate
New Delhi,(PTI): Biotechnology major Biocon today said it has entered into an agreement with Bristol-Myers Squibb for it's oral insulin new drug candidate IN- 105.
Under the terms of the option agreement, Bristol- Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide licence to the programme.
It will, however, conduct the clinical trials according to a pre-agreed development programme up to the completion of Phase II, as per the agreement, Biocon said.
- Number of beneficiaries of scheme for pregnant women drops by 82.6% in city
- City’s oldest police station is abound with stories from pages of history
- Trapped leopard dies, Meerut wakes up to lurking menace
- MHADA asks cops to probe case of Army widows from Satara being duped of flats
- Sasaram youth question Meira Kumar, think Modi has answers
- City’s maternal mortality rate at alarming 158